Ulf Björklund
Chairman at REDWOOD PHARMA AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Andreas Gerward | M | 36 | 10 years | |
| Gudrun Anstrén | F | 69 | 6 years | |
| Olle Carl Hernell | M | 79 | 14 years | |
| Mattias Münnich | M | 45 | 9 years | |
| Martin Vidaeus | M | 58 | 12 years | |
| Hans Ageland | M | 63 | 12 years | |
| Åsa Kristina Hansdotter | F | 50 | 3 years | |
| Hakan Magnusson | M | - | 1 years | |
| Kicki Johansson | M | 66 | 6 years | |
| Anders Lehmann | M | 67 | 9 years | |
| Peter Carlsson | M | 59 | 9 years | |
| Susanne Eva Lindqvist | M | 64 | 14 years | |
| Tom Juhani Rönnlund | M | 51 | 1 years | |
| Scott Rocklage | M | 69 |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 8 years |
| Gustav Ingemar Kihlström | M | 71 | 3 years | |
| Bengt Johansson | M | - | 19 years | |
| Einar Pontén | M | 63 | 8 years | |
| Kristian Sandberg | M | - | 5 years | |
| Sonja Marina Norberg | F | 60 | 3 years | |
| Sara Wulf | F | 47 | 6 years | |
| Klaus Christensen | M | 56 | 5 years | |
| Anna Maria Christina Stålenbring | F | 63 | 4 years | |
| Jarkko Kalliomäki | M | 65 | 1 years | |
| Peter Hencz | M | - | 3 years | |
| Sara Richardson | F | 53 | 3 years | |
| Jonas Carpvik | M | 56 | 4 years | |
| Hans Christian Øiestad | M | - | - | |
| Jessica Candemar | F | - | - | |
| Andreas Andersson | M | - | - | |
| Nada Möller | F | - | - | |
| Per Gunnar Fernström | M | 74 | 3 years | |
| Jane Buus Laursen | M | 49 | 6 years | |
| Frida Edvinsson | F | - | - | |
| Thomas Pålsson | M | 72 | 6 years | |
| Dennis Bang Henriksen | M | 62 | 8 years | |
| Emil Svahn | M | 38 | - | |
| Pernilla Abrahamsson | M | 52 | 5 years | |
| Bernd Seizinger | M | 67 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 9 years |
| Bengt Gerdin | M | 77 |
OxyPharma AB
| 21 years |
| Carl-Johan Spak | M | 68 | 1 years | |
| Peter Rooslien | M | 68 | 8 years | |
| Lars Kärnerud | M | 74 | 8 years | |
| Erik Kinnman | M | 66 | 4 years | |
| Ola Sandborgh | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christian Schade | M | 63 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 6 years |
| Charles de Chasteigner du Mée | M | - | 5 years | |
| Charles P. du Mée | M | 69 | 5 years | |
| Ingrid Atteryd Heiman | F | 66 | 7 years | |
| Gunnar Mattsson | M | 60 | - | |
| Göran Eckerwall | M | 68 | - | |
| Bengt Daniel Furberg | M | 83 | - | |
| Wenche Nelly A. Rolfsen Sandsborg | M | 72 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | - |
| Jonathan Hepple | M | 53 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | - |
| Guido Magni | M | 70 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 4 years |
| Per-Ola Forsberg | M | 63 | 4 years | |
| Ulla Hald Buhl | F | 60 | 6 years | |
| Jan Nilsson | M | 71 | - | |
| Johan Rutger Christenson | M | 65 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | - |
| Björn Oskar Larsson | M | 59 | 1 years | |
| Peter Morsing | M | 66 | 3 years | |
| Eva Catharina Bäärnhielm Marklund | M | 72 | 4 years | |
| Peter Buhl Jensen | M | 69 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | - |
| Bengt Glimelius | M | - | - | |
| Martin Olovsson | M | 57 | - | |
| Nicklas Lindland Roest | F | 39 | 1 years | |
| Curt Mikael von Euler-Chelpin | M | 71 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 66 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ulf Björklund
- Personal Network
